DSIP (Delta Sleep-Inducing Peptide)

Overview

DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid neuropeptide first isolated in 1974 from the blood of sleeping rabbits, named for its ability to induce delta-wave (deep) EEG activity when infused into animal brains. Its precise receptor and mechanism in humans remain poorly defined — proposed actions include modulation of NMDA receptors and stress/glucocorticoid pathways. It is marketed for sleep, stress, and recovery, but the human evidence is limited, old, and inconsistent: some small studies suggest effects on sleep or stress measures, while others do not, and no rigorous large trials establish efficacy. It is not FDA-approved, and its long-term safety in humans has not been characterized. Claims should be treated as preliminary and unproven.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Sleep improvement / deep-sleep support (marketed claim; limited and inconsistent human evidence)
• Stress and cortisol modulation — marketed claim, not established in controlled human trials
• General recovery and pain/withdrawal support — marketed claim, largely preclinical or anecdotal

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Whoop — sleep stages (deep/SWS and REM), total sleep, and sleep efficiency (the most directly relevant readout)
• Whoop — HRV and recovery trend as a stress/autonomic proxy
• Subjective — daily check-ins on sleep quality, time-to-fall-asleep, and next-day energy/mood
• Subjective — tolerability (long-term safety is not established, so note anything unusual)

Sources & References

1. [1]Delta sleep-inducing peptide — Wikipedia (discovery, proposed mechanism, inconsistent evidence)
2. [2]Delta sleep-inducing peptide (DSIP) human studies — PubMed